Over-the-counter CBD sleep pill piques Big Pharma interest - Sydney Morning Herald

GlaxoSmithKline will evaluate a treatment from Australian biotech Cann Group as companies race to be the first approved CBD product.

ASX-listed cannabis producer Cann Group has been given a boost after inking a deal with GlaxoSmithKline which could see the pharmaceuticals giant play a key role in the commercialisation of Canns ove… [+2290 chars]

full article...